Protagonist Therapeutics (NASDAQ:PTGX) Coverage Initiated by Analysts at began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGXGet Rating) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock.

Other research analysts have also recently issued reports about the stock. JMP Securities increased their target price on shares of Protagonist Therapeutics from $21.00 to $31.00 and gave the stock a market outperform rating in a report on Wednesday, March 8th. BTIG Research dropped their price objective on shares of Protagonist Therapeutics to $41.00 in a research note on Wednesday, November 16th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to, the stock has a consensus rating of Moderate Buy and an average target price of $35.50.

Protagonist Therapeutics Price Performance

PTGX opened at $22.42 on Thursday. Protagonist Therapeutics has a 12-month low of $6.91 and a 12-month high of $27.41. The business’s fifty day simple moving average is $16.12 and its 200-day simple moving average is $11.24.

Hedge Funds Weigh In On Protagonist Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd bought a new stake in shares of Protagonist Therapeutics in the 1st quarter valued at about $135,000. Lazard Asset Management LLC purchased a new stake in Protagonist Therapeutics during the second quarter valued at approximately $50,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Protagonist Therapeutics by 18.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,536 shares of the company’s stock valued at $93,000 after acquiring an additional 1,337 shares in the last quarter. Quantbot Technologies LP purchased a new position in Protagonist Therapeutics in the second quarter worth $76,000. Finally, Alpine Global Management LLC acquired a new position in shares of Protagonist Therapeutics during the fourth quarter worth $112,000. Hedge funds and other institutional investors own 91.51% of the company’s stock.

About Protagonist Therapeutics

(Get Rating)

Protagonist Therapeutics, Inc a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Featured Stories

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with's FREE daily email newsletter.